Coherus SEC Filings

Coherus Oncology, Inc. entered into a clinical supply agreement with Janssen Research & Development, LLC to support a Phase 1b study in metastatic castration-resistant prostate cancer. The trial will evaluate Coherus’ investigational anti-CCR8 cytolytic monoclonal antibody tagmokitug (CHS-114) in combination with Janssen’s T-cell engaging bispecific antibody pasritamig.

Under the agreement, Janssen will supply pasritamig, while Coherus will act as sponsor of the Phase 1b clinical trial in patients with metastatic castration-resistant prostate cancer. Each company keeps all commercial rights to its own compound, whether used alone or in combination therapies.

The Vanguard Group filed an amended Schedule 13G reporting beneficial ownership of 10,028,893 shares of Coherus Oncology Inc common stock, representing 8.29% of the class. Vanguard reports no sole voting or dispositive power, with 815,663 shares subject to shared voting power and 10,028,893 shares subject to shared dispositive power.

Vanguard explains that an internal realignment on January 12, 2026 means certain subsidiaries or business divisions are expected to report holdings separately on a disaggregated basis, while pursuing the same investment strategies as before. The holdings include securities in the form of rights, and Vanguard states its clients have the right to receive dividends or sale proceeds, with no single other person’s interest exceeding 5%. Vanguard certifies the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Coherus.

Coherus Oncology President & CEO Dennis M. Lanfear reported new equity awards. On January 23, 2026, he received 375,000 restricted stock units of Coherus Oncology common stock at a price of $0. Each RSU converts into one share, with 50% scheduled to vest on May 20, 2027 and 50% on March 20, 2029, subject to his continued service.

He was also granted a stock option for 750,000 shares of common stock at an exercise price of $2.06 per share, expiring January 23, 2036. The option vests as to one-fourth of the shares on the one-year anniversary of January 23, 2026, and the remainder in equal monthly installments thereafter, contingent on continued service. Following these grants, he holds 1,048,235 shares directly, plus indirect holdings of 432,684 shares through a revocable trust and 86,965 shares through an LLC.

Coherus Oncology, Inc.’s Chief Financial Officer, Bryan J. McMichael, reported new equity awards. On January 22, 2026, he received 112,500 restricted stock units of common stock at $0 per share, bringing his directly held common stock to 133,736 shares. These RSUs vest in two equal parts, with 50% vesting on May 20, 2027 and 50% on March 20, 2029, subject to continued service. He was also granted a stock option for 225,000 shares of common stock at an exercise price of $1.59 per share, all held directly. The option vests 25% on the one-year anniversary of January 22, 2026, and the remainder in equal monthly installments over the following three years.

Coherus Oncology, Inc. filed a prospectus supplement tied to its existing Sales Agreement with TD Securities (USA) LLC (TD Cowen), allowing it to sell shares of common stock from time to time in an at-the-market offering program. The company may offer and sell common stock having an aggregate offering price of up to $64,880,054 through or to TD Cowen under this arrangement.

The filing also includes a legal opinion from Latham & Watkins LLP on the validity of the common stock to be issued under the Sales Agreement, along with the related consent and cover page interactive data file as exhibits.

Coherus Oncology, Inc. is registering and offering up to $64,880,054 of its common stock through an at‑the‑market sales program with TD Cowen under an existing Form S-3 shelf. TD Cowen may sell shares into the Nasdaq Global Market under the symbol CHRS and will receive up to 3.0% of gross proceeds as commissions.

The company intends to use any net proceeds for general corporate purposes, including working capital, research and development, commercial activities and capital spending. Coherus reports preliminary unaudited net revenue from continuing operations of approximately $12.7 million for the quarter and $42.2 million for the year ended December 31, 2025, up from $7.7 million and $26.4 million a year earlier, and estimates cash, cash equivalents and marketable securities of about $172.1 million as of December 31, 2025.

Coherus Oncology’s Chief Financial Officer reports a small tax-related share withholding. On January 20, 2026, 1,715 shares of Coherus Oncology, Inc. common stock were automatically withheld by the company at $1.55 per share to cover tax liabilities tied to vesting restricted stock units. This was reported under transaction code F, which typically reflects tax withholding rather than an open‑market trade.

After this withholding, the CFO directly beneficially owned 21,236 shares of Coherus common stock. The footnote clarifies that no shares were sold by the reporting person; the shares were retained by the issuer to satisfy taxes due on equity compensation.

Coherus Oncology President & CEO Dennis M. Lanfear reported an automatic share withholding related to equity compensation. On January 20, 2026, the issuer withheld 11,839 shares of common stock at $1.55 per share to cover taxes due on the vesting of restricted stock units, and no shares were sold by Lanfear in this transaction. After this withholding, he beneficially owned 673,235 shares directly, plus 432,684 shares held by the Lanfear Revocable Trust and 86,965 shares held by Lanfear Capital Advisors, LLC, both entities associated with him.

Coherus Oncology, Inc. filed a current report to share that it is furnishing preliminary, unaudited financial information for the quarter and fiscal year ended December 31, 2025. The company will present preliminary net revenues and levels of cash, cash equivalents and investments at the 43rd Annual J.P. Morgan Healthcare Conference, with this data included in a slide deck furnished as Exhibit 99.1.

Coherus stresses that its financial closing procedures for this period are not yet complete, so final results may differ materially from the preliminary figures, and its independent registered public accounting firm has not reviewed or audited these results. The presentation also contains forward-looking statements, including projected revenue growth of LOQTORZI, which the company notes are subject to significant risks such as financing needs, market acceptance of its products and litigation risks.